AdipoGen Life Sciences

anti-Myosin IIA (non-muscle) (heavy chain), mAb (rec.) (SF9) (ATTO 488)

CHF 420.00
In stock
AG-27B-0010TD-C100100 µgCHF 420.00
More Information
Product Details
Synonyms Cellular Myosin Heavy Chain, Type A; Myosin Heavy Chain 9; Myosin Heavy Chain, Non-muscle IIa; Non-muscle Myosin Heavy Chain A
Product Type Recombinant Antibody
Properties
Clone SF9
Isotype Human IgG2λ
Source/Host Produced without the use of animals. Purified from HEK 293 cell culture supernatant.
Immunogen/Antigen Full length myosin IIA from rat liver.
Label/Conjugates ATTO 488
Application

Immunocytochemistry: (1:1000)

Crossreactivity Drosophila
Human
Mouse
Rat
Specificity

Recognizes human, mouse, rat and drosophila myosin IIA (heavy chain).

Purity ≥95% (SDS-PAGE)
Purity Detail Protein A-affinity purified.
Concentration 1mg/ml
Formulation Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.
Isotype Negative Control

Fc (human) IgG2 Control (rec.)

Other Product Data

anti-Myosin IIA (non-muscle), monoclonal antibody (recombinant) (SF9) (ATTO 488) is composed of human variable regions (VH and VL) (λ-chain) of immunoglobulin fused to the human lgG2 Fc domain and labeled with ATTO 488.

Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage +4°C
Handling Advice Avoid freeze/thaw cycles.
Use/Stability Keep conjugated formats at +4°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description

anti-Myosin IIA (non-muscle), monoclonal antibody (recombinant) (SF9) is an antibody developed by antibody phage display technology using a human naive antibody gene library. These libraries consist of scFv (single chain fragment variable) composed of VH (variable domain of the human immunoglobulin heavy chain) and VL (variable domain of the human immunoglobulin light chain) connected by a polypeptide linker. The antibody fragments are displayed on the surface of filamentous bacteriophage (M13). This scFv was selected by affinity selection on antigen in a process termed panning. Multiple rounds of panning are performed to enrich for antigen-specific scFv-phage. Monoclonal antibodies are subsequently identified by screening after each round of selection. The selected monoclonal scFv is cloned into an appropriate vector containing a Fc portion of interest and then produced in mammalian cells to generate an IgG like scFv-Fc fusion protein.

Product References
  1. Recombinant antibodies selected against subcellular fractions to track endogenous protein dynamics in vivo: C. Nizak, et al.; Traffic 7, 739 (2003)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.